Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here's the link to the CC....
http://services.choruscall.com/links/tpiv150603.html
This probably helped the move a bit....anybody else see this?
Wonder how this may help us moving forward?
http://mobile.reuters.com/article/idUSKCN0PK1U920150710?irpc=932
Whew....didn't know if it was gonna make the close above $3 or not! Glad it did!
Cheers everyone!
Thanks Seel...Just checked in and saw your post while I'm on vacation in Grenada! Thanks for your insight!
Thanks for that info!
Added to starter on the dip...
Yall take out that resistance...hoping in an airplane and will check in after while!
My buddy has etrade and they told him he had to call to buy shares...
I wonder if etrade had a bunch of share short??? Just a guess.
I have etrade and didn't have problems with buying other stocks. Didn't pick up any additional shares of SYN today though
Good call on the market bounce :)
??Thanks for not nipping my arse...that may hurt.
Good Luck skateboarding!
I picked up a starter here this morning. Can anyone tell me the details on O/S? Institutional ownership? Insider ownership.
TIA
Thanks Rk...for some reason I overlooked that. Thanks for posting the link though. I remembered it from the comfort call but really like seeing it in print too!
Thanks again!
AVXL...I picked some up on $heffs exit. It's what I typically do if I like a company long term. Wait for that exit dip ;) if I catch it early enough and have time to do DD I buy and flip which allows for a greater share count on the second entry!
Rk...where was it mentioned that the PII would start this quarter? Won't they need full funds secured before it can begin? I just can't remember where it was mentioned... Thanks in advance!
OT: ADXS started really making progress when they got a new CEO. Thomas Moore had diluted quite a bit before he left which is why they did a reverse split. He always promised shareholders no reverse which is why I believe is one factor in changing CEOs. Of course they had too reverse so they could uplist and that's completely a better long term move for future capital for the company. However, as a shareholder of the company when it traded in the $ .07-15 range I was disappointed with the slow progress and not lining up partnerships to add value before they did the reverse split. Almost got back in post split but decided not too...
I really like their science though and glad they are progressing their Attenuated listeria monocytogenes platform...very interesting stuff.
Happy 4th! Good times to come soon!
SYN!
Thanks Kei! I somehow missed that in my quick oversight. I'll be looking to start a position this next week!
Happy 4th!
Kei...on AVXL I see they have data due in September but quickly glancing I didn't see what data was due out July 23rd. Could you expand on this day a bit? Thanks and happy 4th everyone!
O/S is 185.97 mill shares
Float is 174.14 mill shares
Short interest as of June 15th was 2.6 million shares or 1.5% of the float. This number could be way higher considering the offering was done June 15th but that was the most recent I could find on short interest.
PVCT....more info
They did just do an offering see link and that closed on June 24th...
https://www.pvct.com/pressrelease.html?article=20150619.1
Here's more info on the science and trial progression. The market cap is around $105 million with the 52 week low being $.49.
http://www.futuremedicine.com/doi/pdf/10.2217/mmt.15.8
http://melanomanewstoday.com/2015/06/12/provectus-begins-patient-enrolment-phase-3-trial-pv-10-melanoma/
https://www.pvct.com/presentation/bio-international-2015/
PVCT...I will be watching for a potential entry.
This may be a good bounce play. Currently nearly at 52 week low and they just got this news today. They also have collaborations with Pfizer..
http://finance.yahoo.com/news/provectus-biopharmaceuticals-signs-letter-intent-103000797.html
NEWS -- Provectus Biopharmaceuticals Signs Letter of Intent with Boehringer Ingelheim (China) to Collaborate in Bringing PV-10 to Market in Mainland China, Hong Kong and Taiwan
Date : 07/02/2015 @ 6:30AM
Source : Business Wire
Stock : Provectus Biopharmaceuticals, Inc. (PVCT)
LOI Signed at ESMO GI Addresses Melanoma and Cancers of the Liver
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”), announced today that it has signed a Letter of Intent (the “LOI”) with Boehringer Ingelheim (China) Investment Co. Ltd. (“Boehringer”). The purpose of the LOI is to lay a foundation for the two parties to collaborate in bringing PV-10, Provectus’ novel investigational drug for cancer (“PV-10”), to market in mainland China, Hong Kong and Taiwan. Maxim Group LLC acted as strategic advisor to Provectus in structuring and negotiating the LOI.
Under the terms of the LOI, Boehringer will provide certain commercially reasonable support in the aspects of product registration with the China Food and Drug Administration (“CFDA”), communication preparation, market intelligence and other assistance to Provectus in China to the extent that is within Boehringer’s approved business scope and permissible by Chinese laws.
In return, Provectus will grant Boehringer the first priority to be the exclusive collaborator of Provectus in China for PV-10 in the event that PV-10 is successfully registered and approved by the CFDA. The exclusive collaboration may take the form of exclusive distribution and promotion, exclusive licensing or other agreement, subject to both parties’ mutual agreement. At the appropriate time, Provectus and Boehringer will enter into a definitive agreement, including a non-compete provision, for PV-10 to be exclusively developed, distributed and promoted through the collaboration within China, although there can be no assurance that the parties will enter into a definitive agreement.
In the LOI signed today at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2015 in Barcelona, the two parties have agreed to meet regularly and maintain effective communication in order to move forward with the registration and commercialization of the product and assess the potential cooperation between them in China, which may be adopted in a form of exclusive commercial supply, distribution and promotion, partnership or any other forms suitable to both parties’ interests.
Stephen Doyle, Vice President and Head of Specialty Care, China, at Boehringer, said, “We are impressed with the work the management of Provectus and its researchers have done so far in developing PV-10 as a potential treatment option for melanoma and cancers of the liver. At Boehringer Ingelheim we are committed to research and development in areas of high unmet need such as liver cancer. If successful, we believe that many Chinese patients could benefit from being treated with PV-10. Because of this, and the data generated so far, we are prepared to provide the commercially reasonable support Provectus may need to get PV-10 through the drug development and registration approval process in China.”
Peter Culpepper, CFO and COO of Provectus, said, “We are excited about the potential of PV-10 in China and in commencing a working relationship with Boehringer Ingelheim to bring PV-10 to market there. We are confident that Boehringer Ingelheim’s expertise in navigating the regulatory requirements in China will prove beneficial to us, and we are also confident that a commercial collaboration will benefit both companies. In addition, we believe that a successful partnership with Boehringer Ingelheim in China will provide us with experience in dealing with regulatory systems outside the US and help us take PV-10 to a global marketplace.”
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.
In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.
For more information please visit http://www.boehringer-ingelheim.com
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company’s other clinical trials, including its current phase 3 study in melanoma, can be found at the NIH registry, http://www.clinicaltrials.gov. For additional information about Provectus, please visit the Company’s website at http://www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2014) and the following:
our determination, based on guidance from the FDA, whether to proceed with or without a partner with the fully enrolled phase 3 trial of PV-10 to treat locally advanced cutaneous melanoma and the costs associated with such a trial if it is necessary to complete (versus interim data alone);
our determination whether to license PV-10, our melanoma drug product candidate, and other solid tumors such as cancers of the liver, if such licensure is appropriate considering the timing and structure of such a license, or to commercialize PV-10 on our own to treat melanoma and other solid tumors such as cancers of the liver;
our ability to license our dermatology drug product candidate, PH-10, on the basis of our phase 2 atopic dermatitis and psoriasis results, which are in the process of being further developed in conjunction with mechanism of action studies; and
our ability to raise additional capital if we determine to commercialize PV-10 and/or PH-10 on our own, although our expectation is to be acquired by a prospective pharmaceutical or biotech concern prior to commercialization.c
Looking real good so far!
And the start of C Diff trials too right?
I took his statement in the context of they would have a product manufactured commercially for the trials as well as have manufacturers in place for the progression through trials...AIMO of course
Thanks for reposting! I couldn't find it in my searches since I watched it originally. Got it bookmarked now ;)
Ash...I have done my DD which is why I believe your information is not correct. The article you posted is recent, however, it states they are looking to STILL get the 4.93 million in financing. This number includes the 2.5 million which was just exersized last week. That leaves another 2.43 million to go. So my original cash estimate of 4 million CURRENTLY is still valid. If we stay above $1 for 10 trading days then the company will receive additional cash.
I appreciate your post. I'm just trying to keep the information as factual as possible. If I am wrong on any of this information and someone sees that I am please feel free to correct me.
GLE
Hey Citrati!...good to see you here. Did you pick up a stake here?
Ash....Recent 10q shows right at 1.5 million cash plus the 2.5 million raised. I only come up with 4 million in cash. That's assuming nothing has been spent since March 31st. If I'm misinformed here show me please.
http://quote.morningstar.com/stock-filing/Quarterly-Report/2015/3/31/t.aspx?t=:TPIV&ft=10-Q&d=754d3b80e2106264a8582f7eda18649d
Yep. It almost appears that the sell orders are at market price which is why it drops quickly...AIMO
Ash...I'm long here but they don't have .60 per share in cash. If so please show me....the science will prevail in the end. GLTU
This take down looks orchestrated IMO
Hey Burr...if/when there is an offer presented typically the offer price will be reflected immediately to the current share price. You can sell before the deal is done if you'd like. However, there could be a counteroffer or even multiple bidders which could correlate to an even higher share price. Of course there is a potential risk that the boards counter may not be accepted and the share price could suffer a bit.your shares are open to sell until a deal is finalized and a date set for the signing of the purchase. Hope this answers your question!
Will there be power in the hour??
Would be nice to see it rebound over $1.
Picked up another 3k shares at .83 :)
I've got enough dry powder for another 4k shares. Just waiting to see how this acts the rest of the day....may wait until tmw to see if market sentiment changes
Picked 2k at .93 and 1k at .97
What happened? It went from 3.22 high to now red at $2.80... Crazy! May look to add this gift price...
Good buys coming in!
Greece banks closing is something else that's big deal(not necessarily for TPIV but overall market)....look at NBG pre market. Down 24%...
Shouldn't we have results before them on our PII for C Diff? I see they are expecting results from their PII around mid 16'.